IRMD IRADIMED CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and sale of MRI compatible medical devices, notably IV infusion pumps and patient vital signs monitors for safe MRI environment use
• • New product emphasis: MRidium 3870 MRI Compatible IV Infusion Pump System launched in 2025 with Remote Display Unit for control from MRI control room
• • Strategic shift: Discontinuation of older 3860+ infusion pump in 2026, focusing on new 3870 system; expanded intra-hospital use targeting ICU, ER, and critical care units
• • Quantitative metric: 29 U.S. direct sales reps as of Dec 31, 2025; approximately 13,098 pump system channels and 3,397 vital signs monitors sold cumulatively
• • Noteworthy fact: 2025 first commercial shipment of MRidium 3870; only known non-magnetic MRI compatible IV infusion pump operating up to 15,000 gauss magnetic field

Risk Factors

• • FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors
• • Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials
• • Operational risk: single manufacturing facility in Orlando, Florida vulnerable to hurricanes or natural disasters disrupting production and shipments
• • Competitive risk: mature market for 3880 patient monitoring system with competitors offering lower prices threatening revenue and margins
• • Key-person risk: heavy dependence on founder and CEO Roger Susi with no guaranteed succession plan in place

Management Discussion & Analysis

• • Revenue $83.8M in 2025, up 14.4% YoY from $73.2M in 2024, driven by U.S. sales +$10.0M (16.4%) and international sales +$0.6M (4.8%)
• • Operating margin 31.2% in 2025 vs 30.0% in 2024; gross profit margin stable at 77% both years
• • Best segment: MRI Compatible IV Infusion Pump Systems revenue $31.6M (+18.9%), worst: Services and other $3.9M (-4.1%)
• • Cash from operations $24.9M in 2025 vs $25.6M in 2024; capex $8.4M primarily for new facility; financing outflows $17.6M, increased dividend payments and stock unit settlements
• • Management confident liquidity sufficient for 12+ months; plans to monitor capital needs, potential financing, and invest in R&D, marketing, and possible acquisitions

What are the latest IRMD SEC filings in 2026?

IRADIMED CORP (IRMD) has filed a 10-K annual report on March 6, 2026, a 10-Q quarterly report on May 1, 2026, an 8-K current report on July 31, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IRMD file its most recent 10-K annual report?

IRADIMED CORP (IRMD) filed its most recent 10-K annual report on March 6, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IRMD 10-Q quarterly reports?

IRADIMED CORP (IRMD)'s most recent 10-Q quarterly report was filed on May 1, 2026. SignalX displays every IRMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IRMD filed recently?

IRADIMED CORP (IRMD)'s most recent 8-K was filed on July 31, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IRMD insider trading activity (Form 4)?

SignalX aggregates every IRMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IRMD file with the SEC?

IRADIMED CORP (IRMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IRMD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for IRADIMED CORP (IRMD).

What is IRMD's SEC CIK number?

IRADIMED CORP (IRMD)'s SEC CIK (Central Index Key) number is 1325618. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1325618 to look up all IRMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IRMD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from IRADIMED CORP (IRMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.